Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.
NCTID
NCT05765981
(View at clinicaltrials.gov)
Description
This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.
(Show More)
Development Status
Active
Indication
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Disease Ontology Term
DOID:0090123
Compound Name
VGN-R09b (AADC + NTF)
Sponsor
Shanghai Jiao Tong University School of Medicine
Funder Type
Other
Recruitment Status
Recruiting
Enrollment Count
6
Results Posted
Not Available
Therapy Information
Target Gene/Variant
DDC
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intraparenchymal
Drug Product Type
Viral vector
Target Tissue/Cell
Striatum
Delivery System
Viral transduction
Vector Type
AAV9
Editor Type
none
Dose 1
Undisclosed single dose
Dose 2
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Early phase1
Submit Date
2023-01-18
Completion Date
2029-02-20
Last Update
2023-03-13
Participation Criteria
Eligible Age
24 Months - 7 Years
Standard Ages
Child
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
1
Locations
China
Regulatory Information
Has US IND
False
FDA Designations
Recent Updates
NMPA IND accepted 1/24/24; FDA IND accepted 7/26/24
Resources/Links
News and Press Releases
VGN-R09b, China's First Domestically Developed Gene Therapy Drug for the Treatment of Primary Parkinson's Disease, Approved for Clinical Trials in the United States
About VGN-R09b